Clinical trialPhase 2Unknown
Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer
Nivolumab as add-on to Gemcitabine/S-1 in Metastatic Pancreatic Cancer: a Phase II Trial
- Outcome
- Outcome unknown
- Phase
- Phase 2
- Status
- Unknown
- Study type
- Interventional
- Start
- 1 July 2020
- Expected end
- 31 December 2022
- Enrollment
- 38 participants
- Sites
- 0
- Primary outcomes
- response rate
- Sponsor
- Other
- Results posted
- No
- Last update
- 6 May 2020
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 3
- Builds on itIncorporating nivolumab with preceded gemcitabine and S-1 chemotherapy for patients of metastatic pancreatic cancer: a … DOI 10.62347/njox8790↗
- BackgroundPhase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma. DOI 10.1007/s10637-017-0525-1↗
- BackgroundRandomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced a… DOI 10.1200/jco.2012.43.3680↗